Planned acquisition of Melville Biologics is terminated by Gaithersburg, Md. firm Dec. 20. MedImmune had signed a letter of intent to acquire the division of the New York Blood Center in September ("The Pink Sheet" Sept. 20, 1993, T&G-13). The agreement called for MedImmune to issue $40 mil. in stock for the acquisition; however, in the wake of an advisory committee rejection of MedImmune's RespiGam and a subsequent plunge in MedImmune stock prices, MedImmune does "not believe the Melville acquisition is in the best interest of our shareholders at this time"
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth